2. Signaling Pathways
  3. GPCR/G Protein
    Immunology/Inflammation
  4. CCR
  5. CCR2 Isoform
  6. CCR2 Inhibitor

CCR2 Inhibitor

CCR2 Inhibitors (9):

Cat. No. Product Name Effect Purity
  • HY-P11553B
    DOTA-ECL1i
    		Inhibitor 98.06%
    DOTA-ECL1i is a conjugate of the CCR2 inhibitor ECL1i (HY-P11553) and DOTA. When radiolabeled with 68Ga, DOTA-ECL1i serves as a PET tracer that targets CCR2 expression. DOTA-ECL1i can be used in research related to pulmonary fibrosis, cardiac injury, abdominal aortic aneurysm inflammation, atherosclerosis, head and neck cancer, and pancreatic cancer.
  • HY-N17908
    Viscumneoside V
    		Inhibitor 98.24%
    Viscumneoside V is a plant-derived anti-inflammatory agent present in Viscum album var. coloratum. Viscumneoside V inhibits the expression of MCP-1 and promotes the production of RANTES in LPS-stimulated immune cells. Viscumneoside V can be used for research related to skin rashes.
  • HY-P99781
    Plozalizumab
    		Inhibitor 99.53%
    Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab also ameliorates synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-101713
    Ilacirnon
    		Inhibitor 98.05%
    CCX140 (CCX140-B) is a potent CCR2 antagonist.
  • HY-402739
    CCR2-IN-1
    		Inhibitor
    CCR2-IN-1 (Compound HO11553-TM) is a G protein-coupled receptor CCR2 inhibitor. CCR2-IN-1 slows the progression of idiopathic pulmonary fibrosis. CCR2-IN-1 can be used for the research of idiopathic pulmonary fibrosis.
  • HY-13499
    JNJ-41443532
    		Inhibitor 99.65%
    JNJ-41443532 (CCR2 antagonist 5) is a selective, orally active hCCR2 inhibitor with good binding affinity (IC50=37 nM) and potent functional antagonism (chemotaxis IC50=30 nM). JNJ-41443532 displays a Ki of 9.6 µM for mCCR2 binding. JNJ-41443532 can be used in the research of inflammatory disease.
  • HY-P11553
    ECL1i
    		Inhibitor
    ECL1i is an allosteric, selective CCR2 inhibitor. ECL1i specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis.
  • HY-19009B
    Propagermanium
    		Inhibitor
    Propagermanium is an orally active and selective CCR2 inhibitor. Propagermanium enhances IFN-γ, IL-2, 2',5'-oligoadenylate synthetase, and unspecified cytokine production, and induces mature cytolytic NK cell subsets. Propagermanium reduces HBe antigen and HBV DNA polymerase levels, promotes HBV clearance and lowers serum ALT. Propagermanium downregulates STAT1, inhibits pro-inflammatory microglia polarization, pro-inflammatory cytokine release, and monocyte/macrophage infiltration. Propagermanium can be used for the research of chronic hepatitis B, atherosclerosis, breast cancer, non-alcoholic steatohepatitis, insulin resistance, refractory gastric cancer, multiple myeloma, type 2 diabetes.
  • HY-148100C
    Emapticap pegol scramble negative control
    		Inhibitor
    Emapticap pegol scramble negative control, an oligonucleotide aptamer, is the negative control of Emapticap pegol (HY-148100).